CytoSorbents Corp. (CTSO) is “One to Watch”
November has been a promising month for CytoSorbents Corp. (NASDAQ: CTSO), a critical care immunotherapy company. The New Jersey-based company, specializing in blood purification to control deadly inflammation in critically ill and cardiac surgery patients, reported its financial results for the third quarter ended September 30, 2016. CTSO reported that product sales for the third quarter of this year were up to $2.14 million, a new record, marking the sixth quarter in a row to show substantial growth with sales up by 100% from 2015’s $1.07 million. The jump was attributed to increases in both direct sales and sales through…







